1. In Vivo

It’s Time For A Billion-Dollar Women's Health Fund

Insights From 2023 Rising Leader And Women’s Health Investor, Jessica Federer

 
• By Lucie Ellis-Taitt

Jessica Federer, former chief digital officer at Bayer, talks to In Vivo about making the jump into investing and why women’s health is a rich and deep market set for change.

women’s health investor summit at the NYSE
Women’s health investor summit at the NYSE, May 2023

Jessica Federer was the first chief digital officer for German big pharma Bayer AG, as well as the first woman to hold that role across the biopharma industry. Now, she is managing partner at Supernode Ventures, investing in early-stage companies with a focus on women’s health.

“Small is really a luxury,” Federer told In Vivo when discussing the move from a pharma giant to a new investment group. Founded in 2018, Supernode’s first fund was sector...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.